A phase II study in advanced cancer patients to evaluate the early transition to palliative care (the PREPArE trial): protocol study for a randomized controlled trial by unknown
TRIALS
do Carmo et al. Trials  (2015) 16:160 
DOI 10.1186/s13063-015-0655-8STUDY PROTOCOL Open AccessA phase II study in advanced cancer patients to
evaluate the early transition to palliative care
(the PREPArE trial): protocol study for a
randomized controlled trial
Thamires Monteiro do Carmo1, Bianca Sakamoto Ribeiro Paiva1,2, Milena Ruas de Siqueira1,
Luciana de Toledo Bernardes da Rosa3, Cleyton Zanardo de Oliveira1,2, Maria Salete de Angelis Nascimento4
and Carlos Eduardo Paiva1,2,4,5,6*Abstract
Background: Previous studies have demonstrated the benefit of early integration of palliative care (PC) in oncology.
However, patients continue to receive late referrals to PC even in comprehensive cancer centers. Patients and health
professionals may perceive PC as ‘a place to die,’ and this stigma is a barrier to timely referrals and to patient acceptance
of treatment.
Methods/design: The primary objective is to evaluate the feasibility of psychosocial intervention and PC in patients with
advanced cancer. The patients will be submitted to a series of brief psychosocial interventions that are based on
cognitive behavioral therapy, and patient acceptance and satisfaction will be assessed. In addition, the impact of
these interventions on depressive symptoms will be evaluated. A randomized, open-label, phase II trial with two
intervention arms and a control group will be conducted. Patients who are started on palliative chemotherapy
and who meet the inclusion criteria will be enrolled. The study participants will be recruited from the outpatient
oncology clinics at Barretos Cancer Hospital and will be randomized into one of the following three treatment
arms: Arm A, which will include five weekly psychosocial interventions based on CBT in combination with early
PC; Arm B, which will include early PC only; and Arm C, which will include standard oncologic care. The Hospital
Anxiety and Depression Scale (HADS), the Patient Health Questionnaire (PHQ-9), the Edmonton Symptom Assessment
System (ESAS-br), the Family Satisfaction with End-of-Life Care (FAMCARE)-Patient scale, and the Disease Understanding
Protocol will be used for data collection. The patients will answer these questionnaires at baseline and 45, 90, 120 and
180 days after randomization.
Discussion: Despite evidence of the positive impact of early PC, it is often provided to patients only at later stages. The
inadequate awareness and stigmatization of PC as a place to die are barriers that complicate the early referral. Patients
with advanced cancer may benefit from a psychosocial and educational strategy that adequately prepares them for initial
PC appointments after an early referral to PC. We anticipate that benefits of psychological intervention shall be synergistic
to secondary emotional benefits from the early integration of PC.
Trial registration: This trial was registered on 6 May 2014 with ClinicalTrials.gov (identifier: NCT02133274).
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Approximately 32.6 million people worldwide are living
with cancer that has been diagnosed within the last five
years [1]. Many cancer cases are diagnosed as metastatic
disease despite advances in cancer prevention strategies.
Furthermore, a significant portion of these cases are as-
sociated with disease recurrence during the monitoring
period. These advanced disease cases are eligible for
concurrent or exclusive monitoring by specialized pallia-
tive care (PC) teams. Approximately 6.5 million cancer
patients are in PC worldwide [2].
The World Health Organization has defined PC as ‘an
approach that improves the quality of life (QL) of pa-
tients and families who face a life-threatening illness
through the prevention and relief of suffering. This ap-
proach is based on the early identification, assessment,
and treatment of pain and other physical, psychosocial,
and spiritual problems’ [3]. Therefore, PC should be pro-
vided by a multidisciplinary team that acts integrally in
outpatient, hospital, and/or home environments [4,5].
Temel et al. [6] evaluated the early integration of PC
in non-small cell lung cancer patients who were start-
ing first-line palliative chemotherapy. An improvement
in the QL scores and a decrease in the symptoms of de-
pression were evident 12 weeks after randomization.
Furthermore, they found that the patients who received
early PC were submitted to fewer aggressive treatments
in the final stages of life. A post-hoc analysis inclusively
demonstrated a 2.7-month increase in the overall
survival rate of patients who received PC. A study by
Bakitas et al. [7] evaluated the early introduction of a
psychoeducational program in the treatment of cancer
patients from rural areas in the United States. The au-
thors observed improved QL scores and reduced symp-
toms of depression over time. More recently, a cluster
randomized clinical trial [8] evaluated the early intro-
duction of PC in a general oncology population in
Canada. The main objective of this study was to improve
the spiritual QL of patients 3 months after randomization.
Improvements in the overall QL at 3 and 4 months after
randomization, the spiritual QL after 4 months and
patient satisfaction were observed in the patients who re-
ceived early PC.
Despite evidence of the positive impact of early PC
on the progress of cancer patients, PC is often pro-
vided to patients at later stages even at oncology and
PC reference centers [9]. In Brazil, reliable informa-
tion on how and when cancer patients are referred to
PC is lacking; however, we believe that patients are re-
ferred late to PC. The inadequate awareness and
stigmatization of PC, which is perceived as a place to
die, are barriers that complicate the early referral of
patients to PC [10,11]. The title ‘Palliative Care’, which
implies improvisation or something provisional, hascomplicated patient acceptance of PC within the con-
text of early cancer support during chemotherapy.
Patients who are referred to PC are often anxious at
the first appointment [12], which leads to a high ab-
senteeism rate.
Therefore, the main hypothesis of the present study
is that patients with advanced cancer may benefit from
a psychosocial and educational strategy that adequately
prepares them for initial PC appointments after an
early referral to PC.
Methods/design
Main objectives
The main objectives of this study are as follows:
1. To assess the feasibility of a brief psychosocial
intervention based on cognitive behavioral therapy
(CBT) and early PC in advanced cancer patients,
including patient acceptance and satisfaction.
2. To assess the impact of the intervention on
symptoms of depression at 90 days after
randomization and to compare the differences
between the intervention groups and the control
group and between the intervention groups.
Secondary objectives
The secondary objectives of the study are as follows:
1. To assess the impact of the interventions on
symptoms of depression at 45, 120 and 180 days
after randomization and to compare the differences
between the intervention groups and the control
group and between the intervention groups.
2. To assess the impact of the interventions on anxiety
symptoms at 45, 90, 120 and 180 days after
randomization and to compare the differences
between the intervention groups and the control
group and between the intervention groups.
3. To assess the impact of the interventions on the QL
scores at 45, 90, 120 and 180 days after
randomization and to compare the differences
between the intervention groups and the control
group and between the intervention groups;
4. To assess the impact of the interventions on
symptom scores (pain, fatigue, nausea, drowsiness,
anorexia, dyspnea, and insomnia) at 45, 90, 120 and
180 days after randomization and to compare the
differences between the intervention groups and the
control group and between the intervention groups.
5. To assess the differences in disease awareness at 45,
90, 120 and 180 days after randomization in the
three arms of the trial.
6. To assess the differences in the number of invasive
procedures at the end of life, such as intensive care
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14 to 28 days of life, between the treatment arms.
Study design
This study will be a randomized open-label, phase II
clinical trial with two intervention arms and a control
group. Figure 1 summarizes the study design.
Eligibility criteria
Inclusion criteria
 Age ≥18 years and <75 years.
 Adequate knowledge about the cancer diagnosis.
 First-line palliative chemotherapy.
 Eastern Cooperative Oncology Group Performance
Status (ECOG-PS) ≤2.
 Life expectancy >6 months and <24 months
(according to the medical oncologist).
 One of the following diagnoses: metastatic or
unresectable recurrent breast cancer, stage IIIC or
IV recurrent platinum-resistant ovarian cancer,
metastatic or unresectable recurrent cervix cancer,
metastatic or unresectable recurrent endometrial
cancer, metastatic or unresectable recurrent head
and neck cancer (after previous radiotherapy),
hormone-refractory metastatic or unresectable
recurrent prostate cancer, metastatic or unresectable
recurrent genitourinary cancer, metastatic orFigure 1 Study flowchart.unresectable recurrent non-small cell lung cancer,
extensive-stage or recurrent small cell lung cancer,
or metastatic or unresectable recurrent gastrointestinal
cancer.
Exclusion criteria
Patients can be excluded from the study for any of the
following:
1. Any current psychological treatment due to a
psychological disorder.
2. Current antidepressant use to treat depressive
disorders and/or anxiety.
3. Regular follow-up in the PC department due to
advanced cancer or an immediate referral to PC by
the assistant physician.
4. Any cognitive deficit or attention problem that
could interfere with the ability of patients to answer
questionnaires or understand the study aims
(according to the investigator).
5. A current or previously established diagnosis of any
of the following psychological conditions:
substance-related disorders, schizophrenia and
other psychotic disorders, mood disorders
(depressive disorders, bipolar disorders), anxiety
disorders, dissociative disorders, personality
disorders, and/or a history of a suicide attempt.
6. Single resected metastasis.
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patient safety, compliance with the study, or the
interpretation of the results according to the
investigator.
Data collection and randomization
The psychological intervention will be conducted by
psychologists trained for the study. Data collection will
be conducted by a team of research coordinators from
the Center for Research Support at Barretos Cancer
Hospital (BCH; Barretos, SP, Brazil).
A trained member of the Center for Research Support,
not involved in data collection or statistical analysis, was
assigned to handle the randomization process, using ta-
bles of random numbers. The study participants will be
randomized (1:1:1) into arms A, B or C. Randomization
will be based on blocks of six patients and will be strati-
fied as follows: breast, gynecological, gastrointestinal,
urological, head and neck, and thoracic. The study arms
will be as follows:
1. Arm A (experimental): psychosocial plus early PC,
including five weekly psychosocial interventions
based on CBT plus early PC (a first medical consult
at the Palliative Care Service will be scheduled for 2
to 3 weeks from the study inclusion date and every 3
to 4 weeks thereafter).
2. Arm B (experimental): early PC (a first medical
consult at the Palliative Care Service will be
scheduled for 2 to 3 weeks from the study inclusion
date and every 3 to 4 weeks thereafter).
3. Arm C (no intervention): standard oncologic care.
Measures
The Hospital Anxiety and Depression Scale (HADS) is a
widely used tool for screening cancer patients for anxiety
and depression [13]. The HADS consists of 14 items that
are divided into two subscales of seven items each
(HADS-A and HADS-D). The score for each item
ranges from 0 to 3. A score of 0 is the minimum score
for each subscale, and 21 is the maximum score. The
psychometric properties of HADS have previously been
assessed in the Brazilian population and are considered
adequate [14].
The Patient Health Questionnaire (PHQ-9) is de-
rived from the Primary Care Evaluation of Mental Dis-
orders (PRIME-MD) screening questionnaire for
depressive symptoms, which was originally developed
to screen patients for depression, anxiety, alcohol
abuse, somatoform disorders, and eating disorders
[15]. The PHQ-9 was validated for use in Brazil in
2013 and is considered a useful tool for screening
depression symptoms [16]. The PHQ-9 consists of
nine questions that examine the presence of majordepressive episode symptoms (Diagnostic and Statis-
tical Manual of Mental Disorders IV, DSM-IV) using
the 4-point Likert scale (0 to 3) for a total of 27
points.
The European Organization for Research and Treat-
ment of Cancer Quality of Life Questionnaire Core 15
Pal (EORTC QLQ-C15-Pal) consists of 15 items, and 14
of these items are answered using 4-point Likert-type
scales (1 to 4). In addition, a single item assesses overall
QL, which is measured using a numerical scale that
ranges from 1 to 7. The QLQ-C15-Pal assesses two
functional scales (physical and emotional), two symptom
scales (fatigue and pain), and five single-item scales
(nausea/vomiting, dyspnea, insomnia, loss of appetite,
and constipation) [17]. The EORTC-QLQ-C15-Pal was
validated for use in Brazil in 2013 with adequate psycho-
metric properties [18].
The Brazilian version of the Edmonton Symptom As-
sessment Scale (ESAS-br) consists of a visual numeric
scale with scores of 0 to 10 to assess ten symptoms, in-
cluding pain, fatigue, drowsiness, nausea, depression,
anxiety, loss of appetite, feeling of wellness, breathless-
ness, and insomnia [19]. The ESAS-br was associated
with adequate psychometric properties when used in a
Brazilian population (Paiva et al., unpublished data).
The Disease Awareness Protocol is a translated ver-
sion of the protocol on cancer awareness and treatment
that was used by Temel et al. and was adapted for this
study [6]. This protocol assesses patient perception re-
garding their chance of a cure and the objective of
chemotherapy (see Additional file 1).
The Family Satisfaction with End-of-Life Care (FAM-
CARE)-Patient scale, originally titled FAMCARE, was
developed to assess the satisfaction of family caregivers
of advanced cancer patients with healthcare [20]. Sub-
sequently, Lo et al. [21] modified the original items to
transform this instrument into a 16-item scale for
assessing the satisfaction of patients with advanced
cancer who undergo outpatient treatment. The most
current version of the scale includes 13 items with 5-point
Likert-type scale responses that range from ‘very dissatis-
fied’ (a score of 1) to ‘very satisfied’ (a score of 5) [22]. One
item, ‘emotional support provided by the healthcare team’,
was added to this questionnaire in the present study
because of the nature of the intervention under study. The
Portuguese version that was used in the study underwent
translation, cultural adaptation, and pre-testing according
to Beaton et al. [23].
Interventions
Psychosocial intervention based on cognitive behavioral
therapy methods
Weekly individual sessions of 40 to 50 minutes in dur-
ation will be performed in a properly equipped room
do Carmo et al. Trials  (2015) 16:160 Page 5 of 9for the reception and accommodation of participants.
The care protocol that was developed for the present
study was based on the method of structuring sessions
as proposed by Beck [24] and was adapted from a pre-
vious study [25]. The psychosocial intervention is de-
scribed in detail in Table 1.Table 1 Detailed structured psychosocial and educational inte
Weekly Planned activities
1 • Introduction of the therapist/patient and establishment of rapport
• Objective measurement of depression and anxiety symptoms
• Psychoeducation: disease - explanation of the cancer diagnosis an
symptoms secondary to the cancer; adverse events - an explanati
it? What is it for? For whom is it provided? When is it provided? H
• Delivery of the ‘Educational Booklet’ that was developed specifica
• Establishment of therapeutic goals
• ‘Partnership Agreement’ - the moment when the therapist and th
traveled by both during the five proposed sessions
• Establishment of the dates and times of the sessions
• Session summary and feedback
2 • Assessment of weekly progress and a bridge to the previous sessi
• Objective measurement of depression and anxiety symptoms
• Reinforcement of the therapeutic goals that were set in the previo
• Early PC - description of the benefits of simultaneous monitoring
palliative chemotherapy and presentation of the explanatory figur
• Delivery of the Coping Card2
• Session summary and feedback
3 • Assessment of weekly progress and a bridge to the previous sessi
• Objective measurement of depression and anxiety symptoms
• Anxiety mechanisms: perceived symptoms and how to monitor th
• Relaxing training - image association
• Session summary and feedback
4 • Assessment of weekly progress and a bridge to the previous sessi
• Objective measurement of depression and anxiety symptoms
• Mechanisms of depressive symptoms: perceived symptoms and h
• Identification of automatic thoughts (thought > emotion > behavi
behaviors, and elucidating the key role of thought on emotion an
• Patient preparation for discontinuation following the next session
• Delivery of the Coping Card1
• Session summary and feedback
5 • Assessment of weekly progress
• Objective measurement of depression and anxiety symptoms
• Retrospective of the methods used in the previous sessions, inclu
• Discussion of the patient’s ability to control and understand the p
• General feedback
1The Educational Booklet contains practical information in layman’s terms about the
that are often associated with advanced cancer. This booklet explains the importan
palliative care.
2The Coping Cards were prepared using stimulating sentences, and guidelines will
cards should be read or remembered.Early palliative care
The Palliative Care Unit of BCH offers an outpatient
clinic and an inpatient ward with 52 beds that are dedi-
cated to cancer patients who are receiving PC. Six PC
doctors were asked to participate in this study and have
received training. The Palliative Care Unit includes arvention
d current health status; symptoms - a discussion of uncomfortable
on of adverse events that result from treatment procedures; PC - What is
ow is it provided? Where is it provided?
lly for this study1
e patient sign a commitment to walk together on the path that will be
on
us session
by a PC team for advanced cancer patients who are submitted to




ow to monitor these symptoms
or), explanation of how thoughts affect emotions and therefore
d behavior
ding progress, difficulties, commitment, and learning
rocess as a way to prevent serious symptoms
possible symptoms secondary to chemotherapy treatment and symptoms
ce of the clinical support that is provided by teams that specialize in
be provided during the sessions regarding the appropriate moments when the
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nurse assistants, nutritionists, physical therapists, psy-
chologists, speech therapists, occupational therapists,
music therapists, dentists, and social workers. An evalu-
ation of the research participants by members of the
multidisciplinary team may be requested according to
the evaluation by the primary physician of the study.
All of the patients will be evaluated by PC physicians
every 3 ± 1 weeks, and the first appointment should
occur 2 to 3 weeks after randomization. Therefore, the
first PC appointment will occur after the first two ses-
sions of the psychosocial and educational intervention
for participants who are allocated to Arm A. The ap-
pointments will follow a standard care protocol, which
shall be duly recorded in medical records using a stan-
dardized protocol for filling out the forms.
The participants in Arm C may receive a routine PC
evaluation depending on the indication from the attend-
ing oncologist. The patients in Arms A and B who have
not undergone at least one session of PC and the pa-
tients in Arm A who have not participated in the first
two sessions of the psychosocial and educational inter-
vention will be excluded from the statistical analyses.
Primary outcome measures
The primary outcome measures are listed below:
1. Descriptive results about the feasibility of the
interventions (the average duration of each
intervention session in minutes, the number of
absences and the reasons for non-attendance in the
intervention groups, the accrual rate, and the
reasons for ineligibility).
2. Changes in satisfaction with care from baseline
according to the FAMCARE-Patient scale at days 45,
90, 120 and 180.
3. Changes in depression symptoms from baseline
according to the HADS-D and PHQ-9 at day 90.
Secondary outcome measures
The secondary outcome measures are listed below:
1. Changes in depressive symptoms from baseline
according to the HADS-D and PHQ-9 at days 45,
120 and 180.
2. Changes in anxiety symptoms from baseline
according to the HADS-A at days 45, 90, 120 and
180; the proportion of patients who believe that
their cancer is curable as measured using an adapted
instrument to evaluate patient awareness (all of the
patients will have incurable advanced cancers;
therefore, patients who claim that their disease is
curable will be interpreted as not being adequately
aware of their prognosis).3. Changes in cancer symptoms from baseline
according to the ESAS-br at days 45, 90, 120 and
180; changes in QL from baseline according to the
EORTC QLQ-C15-Pal at days 45, 90, 120 and 180.
Statistical analysis
The demographic and clinical pretreatment characteris-
tics of the patients will be compared between the study
arms (A versus B versus C) using the analysis of variance
(ANOVA) test for independent measurements (for the
continuous variables) and the chi-squared test (for the
categorical variables). Data normality will be assessed
using the Shapiro-Wilk test [26] and the data distribu-
tion patterns. Cohen’s d effect size will be calculated
according to the mean difference between the two
treatment evaluations divided by the pooled standard
deviation of the sample. The analysis of repeated mea-
surements will be performed for each type of outcome
at 45, 90, 120 and 180 days after randomization, and
these results will be compared to those at the beginning
of the study. The effect size will be calculated between
Arms A versus C, B versus C, A versus B, and also
Arms A plus B versus C. The effect size between the
groups will be considered small (0.20 to 0.49), moderate
(0.5 to 0.79) or large (≥0.80) [27]. The scores for depres-
sion and anxiety symptoms and QL will be compared over
time using a mixed model analysis of variance (ANOVA)
for repeated measurements. The disease awareness scores
and the rate of end-of-life invasive procedures will be
compared using the chi-squared test (or Fisher’s exact
test). A P value <0.05 will be considered statistically sig-
nificant. The statistical software SPSS v.21 will be used for
the statistical analyses.
Sample size calculation
For the a priori power analysis, GPower software v.3.0
(Heinrich-Heine-Universität, Düsseldorf, Germany) [28]
was used to calculate the minimum sample size required
for this study. Cohen’s effect size was randomly consid-
ered moderate to large (Cohen’s d = 0.65) according to
decreased HADS-D and PHQ-9 scores when the experi-
mental arms (A or B) were compared with the control
group (Arm C). The estimated sample size would be 39
participants in each arm for a difference between inde-
pendent means, α of 5% (two-tailed hypothesis) and a
power of 80%. Each group shall have a total of 50 pa-
tients considering a monitoring loss rate of 25% to
30%. A study of this size will have 80% power to detect
differences between Arms A plus B versus Arm C on
the depression symptom scores associated with an ef-
fect size of 0.5 and alpha of 5%. This study is prelimin-
ary in nature, and a key objective of this study is to
assess the feasibility and acceptability of a new clinical
intervention. Furthermore, this study aims to assess
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intervention to early PC, which has not been deter-
mined according to the literature and would be useful
in planning a future definitive phase III trial.
Monitoring committee
An independent monitoring committee that consists of
staff from the Center for Research Support (Coordena-
dores de Pesquisa do Núcleo de Apoio ao Pesquisador,
NAP) of BCH will monitor the collection and analysis of
the study data.
Interim data analysis
An interim analysis is planned for 90 days after the inclu-
sion of 20 participants with complete data in each arm. If
Cohen’s effect size between Arms A and B is <0.2 the
authors will consider ways to strengthen the psychosocial
intervention.
Ethical aspects
All of the individuals who meet the inclusion criteria will
be invited to participate in the study. Each participant
will voluntarily sign an informed consent form. The
research protocol for this study was developed according
to the standards of the National Health Council Reso-
lution number 466/12 and the guidelines of the Declar-
ation of Helsinki. The study protocol was approved by
the Research Ethics Committee of the Barretos Cancer
Hospital (n° 699/014).
Discussion
The feasibility and impact of a brief psychosocial and
educational strategy, which is based on CBT, will be
evaluated in patients with advanced cancer who start
palliative chemotherapy to determine whether the pa-
tients will be in a better condition when assessed for the
first time by a PC team. We believe that the benefits of
psychological intervention shall be synergistic to second-
ary emotional benefits from the early integration of PC.
Therefore, this study will evaluate a new strategy for the
transition into PC. Furthermore, the inclusion of early
PC with or without a brief psychosocial and educational
strategy will be compared to standard oncological care in
a control arm (first-line palliative chemotherapy) in which
patients are referred to PC by the attending physician.
Identifying the reasons patients are referred to PC ser-
vices is essential because of the benefits of early PC in
patients with advanced cancer [6-8,29]. Patients are most
likely referred to PC too late even at oncology reference
centers [9]. Two randomized phase III trials [6,7] found
that early PC was associated with lower levels of depres-
sion symptoms compared with standard oncologic treat-
ment. This study aims to confirm this benefit and to
examine whether the psychosocial and educational strategycan reduce depression symptoms over time. This original
approach may be useful in hospitals with settings similar to
those at BCH. This large hospital is dedicated exclusively to
oncology and has a well-structured PC service; how-
ever, this service is associated with significant patient
stigmatization. Patients often perceive the PC unit as
being exclusively for dying patients, which complicates
their acceptance of early referral to PC.
The attribution of meaning is important for detecting
maladaptive behaviors, which are modifiable through in-
terventions according to CBT [30]. CBT is based on the
premise that cognition affects behavior; however, cogni-
tion may be monitored and changed and the desired
behavioral change may be achieved through cognitive
change [31]. CBT aims to enable individuals to identify
and modify their distorted or dysfunctional automatic
thoughts [32]. Evidence suggests that CBT may benefit
advanced-stage cancer patients by reducing anxiety
symptoms, improving QL [33], and decreasing psychiatric
disorders, which have been observed in cancer patients
who were classified as high-risk for the development of
such disorders [25]. Therefore, the study population in
the present study (advanced-stage cancer patients who
start palliative chemotherapy) may be considered at a
high risk for developing depression. Psychoeducation is
another key tool used in CBT. In a previous clinical trial,
cancer patients were submitted to a psychoeducational
intervention. This strategy was effective in improving
disease awareness rates, and the patients were better
equipped to deal with problems, had lower levels of isola-
tion and guilt, and felt a sense of belonging to the group.
A broad sharing of experiences and lessons by other
patients with advanced cancer was observed [34].
The strategy that has been proposed in this study is
novel and has not yet been assessed in this context.
BCH receives patients from all of the states in Brazil,
particularly patients from the Southeast, Midwest and
North regions because this hospital is recognized as a
reference institution in the Brazilian public health sys-
tem. Despite being monocentric, this study will assess
the impact of the intervention in a culturally heteroge-
neous population with different needs, and the results of
this study may be generalized to the entire Brazilian
population.
The study has several limitations and challenges. The
main limitation is the small sample size. This study is
preliminary and will assess the feasibility of a new inter-
vention and provide initial data on the magnitude of its
benefit. Therefore, the statistical significance of this
intervention is less important than the main objectives
of the study. A larger confirmatory study may be neces-
sary depending on the results of this phase II study. This
study will include patients without underlying psycho-
logical problems. We anticipate difficulties in enrolling
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psychological support and use antidepressants as part of
standard care. Another difficulty in enrolling patients
may be the stigma regarding the PC unit and psycho-
logical approaches. However, those difficulties will be an-
alyzed in the feasibility assessment.
Trial status
Patient enrollment in the study began in August 2014.
The last patient is expected to be included in January
2017.
Additional file
Additional file 1: Disease awareness protocol. Description of the
disease awareness protocol used in the study.
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